Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Back

ESC Professional Premium Access

Effects of canagliflozin on cardiovascular and kidney outcomes and mortality in primary and secondary cardiovascular prevention: pooled analysis from the CANVAS program and CREDENCE trial

Session: Optimal risk factor therapy in high risk patients

Topic: Secondary Prevention

Speaker: Doctor A. Sharma (Montreal, CA)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Abhinav Sharma

McGill University Health Centre, Montreal (Canada)

3 presentations

0 follower

5 more presentations in this session

Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia

Speaker: Ms B. Heidemann (Utrecht, NL)

Icosapent Ethyl diminishes CVD risk in smokers: REDUCE-IT smoking

Speaker: Professor M. Miller (Philadelphia, US)

Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia

Speaker: Doctor A. Wiegman (Amsterdam, NL)

The effect of achieving LDL-C <1.8 mmol/L to prevent the first atherosclerotic cardiovascular events in the primary prevention settings of severe heterozygous familial hypercholesterolemia

Speaker: Doctor S. Funabashi (Tokyo, JP)

Clinical consequences of the lipid-lowering treatment in patients with acute coronary syndrome: real-world retrospective study (LipidACS study)

Speaker: Doctor J. Alarcon (Donostia, ES)

Access the full session

Optimal risk factor therapy in high risk patients

Speakers: Doctor A. Sharma, Ms B. Heidemann, Professor M. Miller, Doctor A. Wiegman, Doctor S. Funabashi...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources